Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells

Triple-negative breast cancers (TNBC) are unlikely to respond to hormonal therapies and anti-HER2-targeted therapies. TNBCs overexpress EGFR and exhibit constitutive activation of the PI3K/AKT/mTOR signalling pathway. We hypothesized that simultaneously blocking EGFR and mTOR could be a potential th...

Descripción completa

Detalles Bibliográficos
Autores principales: El Guerrab, Abderrahim, Bamdad, Mahchid, Bignon, Yves-Jean, Penault-Llorca, Frédérique, Aubel, Corinne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156377/
https://www.ncbi.nlm.nih.gov/pubmed/32286420
http://dx.doi.org/10.1038/s41598-020-63310-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156377/
https://www.ncbi.nlm.nih.gov/pubmed/32286420
http://dx.doi.org/10.1038/s41598-020-63310-2

Ejemplares similares